A major pillar of cancer immunotherapy involves stimulating T cells, the specialized killers of the immune system, to attack tumors. But this strategy has been undermined by the tendency of T cells to tire out before finishing the job. When the cells reach the fatigued stage — called T cell exhaustion — these immune cells lose the ability to sustain the attack and keep cancer growth under control.
This has been a significant problem with checkpoint inhibitor drugs, a type of immunotherapy that releases a brake on T cells to spur them into action.
“A tragic part of T cell exhaustion is that the immunotherapy seems to be working for patients, and then it fades,” says Santosha Vardhana, MD, PhD, a physician-scientist at Memorial Sloan Kettering Cancer Center (MSK) who treats people with lymphoma. “Many of them experience a brief wisp of promise only to have it taken away.”
Now the lab of Dr. Vardhana has identified a signaling molecule called MEK that plays a key role in T cell exhaustion. The finding, based on animal studies and published in Immunity, suggests blocking MEK could potentially limit T cell exhaustion and give a dramatic boost to immunotherapy.
“We’re excited about applying this finding to enhance multiple forms of immunotherapy,” Dr. Vardhana says. “FDA-approved MEK inhibitors are already available, so this approach could be tested in humans without much delay.”
T cell strength, metabolism, and the role of MEK
Until recently, researchers did not fully understand how T cell exhaustion occurs. But in 2020, Dr. Vardhana’s lab found an important clue: It starts with the cells’ metabolism — the chemical processes that enable cells to produce energy from nutrients.
Continuous exposure to tumor antigens (the cancer proteins the immune system sees as foreign) can overtax a part of the T cell called the mitochondria — otherwise known as the “powerhouse” of the cell — which are responsible for converting nutrients into energy.
“There is a large metabolic demand being imposed as T cells encounter cancer cells and try to produce cancer-killing, or cytotoxic, proteins,” Dr. Vardhana says. “It turns out that the decision to make high levels of these proteins is regulated by MEK.”
When MEK becomes hyperactive, it eventually drives the T cells into a terminally exhausted state — so depleted that immunotherapy can’t stimulate them.
The researchers realized that limiting MEK signaling could tamp down the drive to produce cytotoxic proteins, helping some T cells remain in an active, self-renewing state for longer. This could potentially improve the effectiveness of immunotherapy.
Think of it as adjusting your speed over the course of an entire road trip rather than driving full throttle the whole way — by slowing down, you preserve your capacity to keep going much longer.
The researchers demonstrated in lab models that blocking MEK signaling enabled T cells to persist, even under the harsh environmental conditions of the tumor.
But when it comes to cancer patients, one size doesn’t fit all. Shutting down MEK may not be the best option for all patients.
A balancing act: supercharging T cells versus preserving energy
T cell exhaustion is more complex than researchers first suspected. For example, MSK immunologist Andrea Schietinger, PhD, discovered that T cells enter the exhausted state to save themselves. They stop fighting to avoid becoming overstimulated and dying.
“As we’ve learned more about T cell exhaustion,” Dr. Vardhana says, “we’ve increasingly understood that it’s not the case that exhausted T cells are bad, so let’s try to reverse the process with a drug. Instead, exhaustion is more of an equilibrium state that lets the cells survive and keep going — almost like a ‘safe mode’ for T cells.”
When a T cell is in attack mode and making cytoxic proteins, the mitochondria must convert nutrients from food into adenosine triphosphate (ATP). ATP is the primary molecule used by all living cells to store and transfer energy.
“Think of ATP as the currency in a fund that the cell spends down,” Dr. Vardhana says. “If you spend ATP on one thing, you don’t have enough to do something else. The exhaustion program is a sign that the cell’s bank account is getting close to zero. MEK tells exhausted cells whether to conserve fuel or go for broke. What we found is that inhibiting MEK makes the cells more conservative — helping them live longer while reducing the rate at which they produce the proteins that actually kill cancer cells.”
So MEK is both the problem and part of the solution — it keeps T cells at full power but risks complete burnout. This means blocking MEK is a double-edged sword: It weakens the attack but keeps the soldiers alive.
Is it better to have a powerful immune attack that burns out quickly or a more subdued attack that lasts? The answer may depend on each person’s cancer.
When to hit the gas and burn through T cells
Dr. Vardhana explains how MEK inhibitors should be used selectively to rev up T cells. Two factors indicate patients will respond well to immunotherapy:
- The tumors are small.
- The patients have a high number of immune cells attacking the tumor — usually because the tumor has many mutations that make it recognizable.
“In these patients, conservation of T cells is not that important,” he says. “It’s like being in a car with 1/8 of a tank left, but you can see the finish line. In these patients, you would just let the car keep burning the gas — in other words, take the traditional immunotherapy approach. These are the patients in whom MEK inhibition is probably not needed.”
In contrast, patients with large tumors or a small number of immune cells are unlikely to have a strong enough response to immunotherapy to finish off the tumor quickly. In those cases, a MEK inhibitor-induced slow burn — even in an exhausted state — allows T cells to persist, which is essential when when either the task at hand (the tumor) is large or the workforce (the number of T cells) is small.
Multiple immunotherapy applications
Dr. Vardhana says MEK inhibition, used prudently, could enhance several types of immunotherapy:
- Checkpoint inhibitors: MEK inhibition has already been effective in treating melanoma when given along with checkpoint inhibitors and a targeted therapy called a BRAF inhibitor.
- Chimeric antigen receptor (CAR) T cell therapy: “We think this approach could dramatically boost T cell persistence, which has been a big problem with CAR T cell therapy,” Dr. Vardhana says.
- Tumor infiltrating lymphocyte (TIL) therapy: TIL therapy harnesses and expands the power of immune cells that have already been fighting the cancer. MEK inhibition, done either before or after TIL therapy is administered, may enable the best tumor-fighting TILs to persist.
- Bispecific antibodies: This new class of drug consists of lab-made proteins designed to bind to two different targets simultaneously, which can drive T cell hyperactivation but may also cause exhaustion.
“This study shows the importance of understanding core principles of T cell biology — what sets the balance between conservation of energy and strong, cancer-fighting activity,” Dr. Vardhana says. “Once we know the answer to that, the therapeutic possibilities really start to fan out.”
Key Takeaways
- Immune T cells often become exhausted and lose their power when recognizing and responding to cancer.
- A signaling molecule called MEK plays a key role in causing T cell exhaustion.
- Blocking MEK can slow the process of T cell exhaustion, potentially enhancing the T cell attack on cancer.
- This therapeutic strategy is likely to have the greatest value in patients who don’t respond to traditional immunotherapy — those with large tumors or very few tumor-reactive immune cells.
Additional authors, funding, and disclosures
Additional authors on the study include Tanmana Mitra, Jahan Rahman, Madeline Hwee, Yan-Ting Chen, Ruben Jose Jesus Faustino Ramos, Hui Liu, Travis Hartman, Justin Cross, Miguel de Jesus, Morgan Huse, Valerie Longo, and Pat Zanzonico.
The study was supported by an NCI K08 Career Development Award (NCI K08 CA237731), a Burroughs Wellcome Fund Career Award for Medical Scientists, a V Foundation Scholar Award, and the Josie Robertson Investigators program. This work was additionally supported by a Cancer Center Support Grant (P30 CA008748) and the Dorris J. Hutchison Pre-doctoral Fellowship by Memorial Sloan Kettering.
Dr. Vardhana has provided consulting services for Generate:Biomedicines and has received research funding from Bristol Myers Squibb unrelated to this work.
Read the study: “MEK-dependent bioenergetic demand drives terminal CD8+ T cell exhaustion”, Immunity. DOI.10.1016/j.immuni.2026.06.012